The aim of this study was to determine the role of AKT as a therapeutic target in ovarian clear cell
carcinoma (CCC), an aggressive, chemoresistant histologic subtype of
ovarian cancer. AKT activation was assessed by immunohistochemistry (IHC) using human tissue microarrays of primary
ovarian cancers, composed of both CCC and serous
adenocarcinoma (SAC). The growth-inhibitory effect of AKT-specific targeting by the small-molecule inhibitor,
perifosine, was examined using ovarian CCC cell lines in vitro and in vivo. Finally, the activity of
perifosine was examined using in CCC-derived
tumors that had acquired resistance to anti-
VEGF or chemotherapeutics such as
bevacizumab or
cisplatin, respectively. Interestingly, AKT was frequently activated both in early-stage and advanced-stage CCCs. Treatment of CCC cells with
perifosine attenuated the activity of AKT-mTORC1 signaling, inhibited proliferation, and induced apoptosis. The effect of
perifosine was more profound under conditions of high AKT activity compared with low AKT activity. Increased AKT activation and enhanced sensitivity to
perifosine were observed in the context of
cisplatin-resistant CCC. Treatment with
perifosine concurrently with
cisplatin significantly enhanced the antitumor effect of
cisplatin. Moreover,
perifosine showed significant antitumor activity in CCC-derived
tumors that had acquired resistance to
bevacizumab or
cisplatin. Collectively, these data reveal that AKT is frequently activated in ovarian CCCs and is a promising therapeutic target in aggressive forms of
ovarian cancer.
IMPLICATIONS: